SLC5A2 and hydrops fetalis: Future research should prioritize the following: IPD meta-analyses to explore nuanced phenotypes and sex-specific responses; integration of SGLT2 inhibitors with emerging HFpEF therapies; mechanistic studies exploring tissue-level metabolic, inflammatory, and microvascular pathways; long-term assessment of functional capacity and quality-of-life endpoints; comparative trials between different SGLT2 agents in distinct HF subgroups; real-world evidence evaluating treatment sequencing and combination therapy.